Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) announced that AstraZeneca has submitted a new drug marketing application to the US Food and Drug Administration (FDA) for the treatment of a combination of Vorosha® (ORPATHYS®, savolitinib) and TAGRISSO® (TAGRISSO®, osimertinib) to treat patients with MET during or after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Patients with locally advanced or metastatic non-small cell lung cancer expressed or amplified.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.